Melatonin shows promising but not yet proven benefits for COVID-19. Several clinical trials have tested it as an add-on treatment, and the results suggest it may help reduce inflammation and improve recovery, but no major health authority has formally recommended it as a COVID-19 therapy. The evidence is encouraging enough that researchers keep studying it, yet not strong enough to call it a reliable treatment.
What the Clinical Trials Show
At least eight randomized controlled trials have tested melatonin in COVID-19 patients, using doses ranging from 3 mg per day up to 24 mg per day, with treatment lasting anywhere from five nights to two weeks. A systematic review and meta-analysis published in Frontiers in Medicine pooled the results of these trials to look for consistent patterns in mortality, hospital stay length, and symptom improvement.
The doses varied widely across studies. Some gave patients a modest 3 mg at bedtime, similar to what you’d find on a drugstore shelf. Others used much higher doses, up to 21 or 24 mg daily, sometimes delivered through a feeding tube for critically ill patients. This inconsistency makes it hard to draw firm conclusions about how much melatonin might actually help, or what the right dose would be. Most studies also combined melatonin with standard COVID treatments, so it’s difficult to isolate melatonin’s contribution.
How Melatonin Might Help During Infection
The severity of a COVID-19 infection depends less on the virus itself and more on the immune system’s response. In serious cases, the body overreacts with a flood of inflammatory signals, sometimes called a cytokine storm, that damages the lungs and other organs. Melatonin appears to work on several fronts against this process.
It dials down the overreaction of the innate immune system, which is the body’s first and bluntest line of defense. At the same time, it supports the adaptive immune system, the more precise branch that produces antibodies. Lab research also suggests melatonin may interfere with the virus’s ability to enter cells and replicate, though this hasn’t been clearly demonstrated in humans. The combination of calming excessive inflammation while still supporting targeted immune function is what makes melatonin theoretically appealing as an add-on therapy.
Safety at Higher Doses
One consistent finding across studies is that melatonin has a large safety margin. A meta-analysis of 50 studies found that oral melatonin, even at doses between 1 and 20 mg, caused only minor side effects like drowsiness, fatigue, and occasional headaches. In one older study, participants took one gram of melatonin daily (1,000 mg, far beyond any COVID trial dose) for a month with no serious adverse effects.
That said, the doses used in COVID trials (often 6 to 24 mg daily) are significantly higher than the 0.5 to 5 mg range commonly sold for sleep. If you’re considering higher doses, it’s worth knowing that prolonged or high-dose use carries uncertain long-term effects on the endocrine system. Short courses of a few weeks, like those used in the clinical trials, appear well tolerated.
Melatonin and Long COVID
There’s a separate and growing interest in melatonin for long COVID, particularly for the widespread pain, fatigue, sleep problems, and cognitive difficulties that persist for months after infection. The connection isn’t just about sleep. Chronic inflammation from long COVID appears to disrupt the body’s own melatonin production, creating a cycle: inflammation impairs melatonin levels, poor sleep worsens inflammation, and both amplify pain.
Melatonin’s antioxidant and anti-inflammatory properties could theoretically break that cycle. It regulates circadian rhythms and supports mitochondrial function (how cells produce energy), which may help with fatigue and cognitive symptoms. Research published in Frontiers in Pain Research notes that by improving sleep quality, melatonin can indirectly reduce pain perception, since disrupted sleep is one of the biggest factors that makes chronic pain worse. However, dedicated clinical trials testing specific doses for long COVID symptoms are still needed before this moves from plausible theory to established practice.
What This Means Practically
Melatonin is not a substitute for vaccines, antivirals, or other proven COVID-19 treatments. No major clinical guideline currently recommends it specifically for COVID-19. What the research does suggest is that it’s a low-risk supplement with biological properties that align well with what goes wrong during severe COVID: excessive inflammation, oxidative stress, and immune dysregulation.
If you’re dealing with an active COVID infection and already take melatonin for sleep, there’s no reason to stop. The clinical trials used it alongside standard treatments, not as a replacement. For long COVID symptoms like persistent insomnia, fatigue, or widespread pain, melatonin’s established role in sleep regulation and its anti-inflammatory effects make it a reasonable option to discuss with your doctor, particularly since the side effect profile is mild even at higher-than-typical doses.
The biggest limitation is that researchers haven’t settled on an optimal dose, timing, or duration for COVID-related use. Trial doses ranged from 3 mg to 24 mg daily, and until larger studies narrow that window, there’s no standard protocol to follow.